Your selection

Innovation / 14.02.2020
Eckert & Ziegler Starts Development Cooperation for Prostate Cancer Diagnosis

The Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) and the Israeli Isotopia Molecular Imaging Ltd. (Isotopia) will in future work more closely together in the early detection of prostate cancer and to this end recently concluded an agreement on the joint development and approval of diagnostic reagents. As part of the agreement, the production of these substances shall soon be fully automated through the use of synthesis systems.
 
Eckert & Ziegler has long been developing and marketing so-called synthesis modules, which are used to prepare short-lived diagnostic reagents in hospitals for tumor diagnosis. So far, one important application field is the production of diagnostics for neuroendocrine tumors (NETs) on the basis of Gallium-68.  The new strategic collaboration is intended to ensure that the synthesis modules also will be able to use Isotopia´s simplified method to produce Gallium-68 based diagnostic reagents for the detection of prostate carcinomas in the future.
 
"Our synthesis modules simplify the work of physicians and medical physicists, so any expansion of the field of application makes sense," said Dr. Sven-Peter Heyn, Managing Director of Eckert & Ziegler Eurotope GmbH and responsible for the Lab Devices division. "We hope that this step will not only lead to higher sales of synthesis modules in the medium term, but also to a competitive advantage for our gallium generators, which are compatible to the devices.
 
About Eckert & Ziegler.

Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.
 
Contact:

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de

www.ezag.de Source: Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG

Overview News

News Buch Berlin

FyoniBio, Alder Therapeutics, and BioLamina enter Consortium Grant Agreement to Propel Recombinant Human Laminin Development for Clinical Applications

FyoniBio, a contract development organization (CDO) specializing in customized cell line and process development has partnered with BioLamina, a biotech company renowned for its expertise in extracell...

more ...

Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals

Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreeme...

more ...

Third ERC Grant for Gaetano Gargiulo

Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max D...

more ...

Events Buch Berlin

30.03.2024, 15:00
Osterfeuer auf dem historischen Stadtgut Berlin-Buch

19.04.2024, 08:30
Lehrkräftekongress: Gemeinsam Schüler:innen für Naturwissenschaften begeistern - gemeinsam Zukunft gestalten

Der Verband der Chemischen Industrie e.V., Landesverband Nordost, das Max Delbrück Center, das Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V., das Gläserne La...

more ...

06.05.2024, 09:00
Realtime PCR und digital PCR Kurs

Der RealTime PCR und Digital PCR Kurs richtet sich an erfahrene PCR Anwender*innen und an Einsteiger*innen. Wichtige PCR Grundlagen werden erörtert, bevor die RealTime PCR besprochen und Genexpression...

more ...

This website is supported by: